在ccRCC中解码苏尼替尼抗性:代谢重编程诱导的ABAT和GABAergic系统转移
Qian Zhang1,2, Lei Ding1, Ye Yan3
1Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
iScience
|August 5, 2024
概括
清细胞细胞癌 (ccRCC) 中的ABAT降低会通过增加GABA,激活SYK/LYN,并上调PGF而导致苏尼替尼抗性. 抑制SYK/LYN或将LYN抑制剂与sunitinib结合起来可以克服这种抵抗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 清细胞细胞癌 (ccRCC) 是一种主要的癌症类型,使用sunitinib治疗.
- 对苏尼提尼布的耐药性是ccRCC治疗中的一个重大临床挑战.
- 代谢重编程是ccRCC的标志性特征,并与耐药性有关.
研究的目的:
- 调查代谢基因ABAT在ccRCC中苏尼替尼抗性的作用.
- 为了阐明底层的分子机制ABAT介导的苏尼提尼布耐药性.
- 确定潜在的治疗策略,以克服ccRCC中苏尼提尼布耐药性.
主要方法:
- 在ccRCC中对ABAT进行定量基因表达分析.
- 测量细胞内的胺黄油酸 (GABA) 水平.
- 对G蛋白结合受体GABA-B激活的评估.
- 对氨酸激酶受体 (SYK和LYN) 交换活化的分析.
- 在体外和体内评估sunitinib的抗瘤和抗血管原作用.
- 使用SYK和LYN抑制剂的抑制研究.
- 对于PGF蛋白水平的西方斑点分析.
主要成果:
- 在ccRCC中,ABAT表达显著下降,与降低的苏尼替尼敏感性相关.
- 降低ABAT调节导致细胞内GABA增加,激活GABA-B受体.
- GABA-B激活导致SYK和LYN的交换激活,从而降低了sunitinib的疗效.
- SYK和LYN的交换活化提高了PGF的调节,调节了对sunitinib抗血管效应的抵抗力.
- 抑制SYK和LYN,或与LYN抑制剂和sunitinib联合治疗,恢复敏感性和增强治疗效果.
结论:
- 通过GABA-B/SYK/LYN/PGF通路,ABAT下调是推动ccRCC中苏尼替尼抗性的关键机制.
- 针对GABA-B/SYK/LYN途径或结合疗法提供了一种有前途的策略,以克服sunitinib耐药性.
- 对代谢重编程和向治疗的进一步研究对于改善ccRCC治疗结果至关重要.
更多相关视频
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
33.6K
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.6K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
